Subscribe
cecilie_arcurs
cecilie_arcurs / iStockphoto.com
29 August 2017Americas

Gilead Sciences to acquire Kite Pharma for $11.9bn

Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead follows Kite acquisition with $567m buy
12 December 2017   Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.
Americas
Pfizer and Allogene partner to develop cancer therapies
5 April 2018   Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Gilead follows Kite acquisition with $567m buy
12 December 2017   Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.
Americas
Pfizer and Allogene partner to develop cancer therapies
5 April 2018   Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.

More on this story

Americas
Gilead follows Kite acquisition with $567m buy
12 December 2017   Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.
Americas
Pfizer and Allogene partner to develop cancer therapies
5 April 2018   Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool